Last Updated : April 16, 2025
Details
Generic Name:
setmelanotide
Project Status:
Not filed
Therapeutic Area:
Weight management for pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency
Manufacturer:
Rhythm Pharmaceuticals, Inc.
Brand Name:
Imcivree
Project Line:
Reimbursement Review
Project Number:
NS0041-000
Biosimilar:
No
Fee Schedule:
N/A
Indications:
For weight management in adult and pediatric patients 6 years of age and older with obesity due to genetically confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : April 16, 2025